Gene Therapy Market, 2018-2030 – ResearchAndMarkets.com – Business Wire (press release)
|
Gene Therapy Market, 2018-2030 – ResearchAndMarkets.com
Business Wire (press release) The year 2017 was particularly eventful; despite the withdrawal of Glybera from the European market in early 2017, the latter half of the year witnessed the approval of two gene therapies, namely Invossa and Luxturna. In fact, Luxturna became the first … Worldwide Hemophilia Gene Therapy Market by 2023 Opportunities, Strategies, Challenges, Supply, Demand, Market … |
